|
시장보고서
상품코드
1507198
MCED(다중 암 조기 발견) 시장, 점유율, 규모, 동향, 산업 분석 보고서, 예측(2024-2032년)Multi Cancer Early Detection Market Share, Size, Trends, Industry Analysis Report Forecast, 2024 - 2032 |
||||||
Polaris Market Research의 최신 조사에 따르면, 세계 MCED(다중 암 조기 발견) 시장 규모는 2032년까지 39억 3,479만 달러에 달할 것으로 예상됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 인사이트와 향후 시장 성장에 대한 분석을 제공합니다.
MCED(다중 암 조기 발견) 시장은 유전체학, 생명공학, 인공지능의 발전으로 빠르게 진화하고 있습니다. 이 시장은 종종 혈액 검사와 같은 비침습적 방법을 사용하여 하나의 샘플에서 여러 암종을 검출할 수 있는 진단 검사의 개발 및 상용화에 초점을 맞추고 있습니다. 그 목적은 암을 치료할 수 있는 초기에 발견하여 환자의 예후를 개선하고 의료 비용을 절감하는 것입니다.
암 조기 진단 시장의 성장에는 몇 가지 요인이 있습니다. 첫째, 전 세계적으로 암 발병률이 증가하고 조기 발견의 이점에 대한 인식이 높아지면서 혁신적인 진단 솔루션에 대한 수요가 증가하고 있습니다. 세계보건기구(WHO)에 따르면, 암은 전 세계 주요 사망 원인이며, 향후 20년간 신규 발병률이 약 60% 증가할 것으로 예상됩니다. 둘째, 유전체학 및 분자생물학의 기술 발전으로 암을 조기에 발견할 수 있는 민감하고 특이적인 바이오마커가 개발되고 있습니다. 각 기업들은 이러한 진보를 활용하여 일상적인 임상에 통합될 수 있는 다양한 암 선별 검사를 개발하고 있습니다.
또한, 공공 및 민간 부문의 연구개발(R&D)에 대한 막대한 투자가 이 분야의 혁신 속도를 가속화하고 있습니다. 정부와 보건 기관들도 조기 발견 이니셔티브를 지원하려는 움직임을 강화하고 있으며, 생명을 구하고 장기적으로 의료비 지출을 절감할 수 있는 잠재력을 인식하고 있습니다. 또한, 개인 맞춤형 의료의 확산과 예방 의료로의 전환은 MCED(다중 암 조기발견) 검사를 보다 광범위한 검진 프로그램에 통합하는 것을 촉진하고 있습니다. 이러한 촉진요인을 종합하면 MCED(다중 암 조기 발견) 시장은 향후 몇 년 동안 크게 성장하여 암 진단 및 환자 치료를 변화시킬 것으로 예상됩니다.
MCED(다중 암 조기 발견) 시장 보고서 하이라이트
액체 생검에 대한 연구가 증가함에 따라 액체 생검 분야는 가장 빠른 CAGR로 성장할 것으로 예상됩니다.
진단 검사실 부문은 개인 맞춤형 의료에 대한 인식이 높아지고 저렴한 가격에 대한 수요가 증가함에 따라 급격한 성장이 예상됩니다.
APAC은 암 환자 수 증가와 생존율 향상에 대한 필요성이 증가함에 따라 상당한 성장률을 보일 것으로 예상됩니다.
목차
제1장 소개
제2장 주요 요약
제3장 조사 방법
제4장 세계의 MCED(다중 암 조기 발견) 시장 인사이트
- 업계 현황
- MCED(다중 암 조기 발견) 시장 역학
- 성장 촉진요인과 기회
- AI 통합으로 암 검진에 변화를 가져올 다중 암 조기 발견(MCED) 테스트
- 암 탐지 비율 향상
- 성장 억제요인과 과제
- MCED(다중 암 조기 발견) 검사를 둘러싼 잠재적 위험과 불확실성
- 성장 촉진요인과 기회
- Porter's Five Forces 분석
- PESTLE 분석
- MCED(다중 암 조기 발견) 업계 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 세계의 MCED(다중 암 조기 발견) 시장 : 유형별
- 주요 조사 결과
- 소개
- 액체 생검
- 유전자 패널, LDT
- 기타
제6장 세계의 MCED(다중 암 조기 발견) 시장 : 최종사용자별
- 주요 조사 결과
- 소개
- 병원
- 진단 실험실
- 기타
제7장 세계의 MCED(다중 암 조기 발견) 시장 : 지역별
- 주요 조사 결과
- 소개
- MCED(다중 암 조기 발견) 시장 평가 : 지역, 2019-2032년
- 북미
- 북미 : 최종사용자별, 2019-2032년
- 북미 : 유형별, 2019-2032년
- 미국
- 캐나다
- 유럽
- 유럽 : 최종사용자별, 2019-2032년
- 유럽 : 유형별,2019-2032
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 아시아태평양
- 아시아태평양 : 최종사용자별, 2019-2032년
- 아시아태평양 : 유형별,2019-2032
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 중동 및 아프리카
- 중동 및 아프리카 : 최종사용자별, 2019-2032년
- 중동 및 아프리카 : 유형별, 2019-2032년
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 남아프리카공화국
- 라틴아메리카
- 라틴아메리카 : 최종사용자별, 2019-2032년
- 라틴아메리카 : 유형별, 2019-2032년
- 멕시코
- 브라질
- 아르헨티나
제8장 경쟁 상황
- 확대와 인수 분석
- 확대
- 인수
- 제휴/협업/합의/공개
제9장 기업 개요
- Illumina, Inc.(GRAIL, LLC)
- Exact Sciences Corp.
- Foundation Medicine, Inc
- AnchorDx
- Guardant Health
- Burning Rock Biotech Ltd
- GENECAST
- Beijing Lyman Juntai International Medical Technology Development Co
- Freenome Holdings, Inc.
- Elypta AB
The global multi cancer early detection market size is expected to reach USD 3,934.79 million by 2032, according to a new study by Polaris Market Research. The report "Multi Cancer Early Detection Market Size, Share & Trends Analysis Report, By Type (Liquid Biopsy, Gene Panel, LDT & Others), By End-use (Hospitals, Diagnostic Laboratories), By Region, And Segment Forecasts, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The multi-cancer early detection market is rapidly evolving, driven by advances in genomics, biotechnology, and artificial intelligence. This market focuses on the development and commercialization of diagnostic tests capable of detecting multiple cancer types from a single sample, often using non-invasive methods such as blood tests. The aim is to identify cancer at an early, more treatable stage, improving patient outcomes and reducing healthcare costs.
Several factors are driving the growth of the multi-cancer early detection market. Firstly, the increasing global incidence of cancer, coupled with the rising awareness of the benefits of early detection, fuels demand for innovative diagnostic solutions. According to the World Health Organization, cancer is a leading cause of death worldwide, with new cases expected to rise by approximately 60% over the next two decades. Secondly, technological advancements in genomics and molecular biology have led to the development of highly sensitive and specific biomarkers that can detect cancer at very early stages. Companies are leveraging these advancements to create multi-cancer screening tests that can be integrated into routine clinical practice.
Additionally, substantial investments in research and development by both private and public sectors are accelerating the pace of innovation in this field. Governments and health organizations are also increasingly supporting early detection initiatives, recognizing their potential to save lives and reduce long-term healthcare expenditures. Furthermore, the growing adoption of personalized medicine and the shift towards preventive healthcare are encouraging the integration of multi-cancer early detection tests into broader health screening programs. Collectively, these driving factors position the multi-cancer early detection market for significant growth in the coming years, promising to transform cancer diagnostics and patient care.
Multi Cancer Early Detection Market Report Highlights
The liquid biopsy segment is anticipated to grow at the fastest CAGR, owing rise in research towards liquid biopsies
The diagnostic laboratories segment will grow with rapid pace, due to the increased awareness of personalized medicine, rise in demand for affordable services
APAC expected to witness substantial growth rate, due to rising number of cancer cases and rising need to increase survival rate
The global players include Illumina, Sciences Corp., Foundation Medicine, AnchorDxFreewomen, and Elypta
Polaris Market Research has segmented the Multi Cancer Early Detection Market report based on type, end use, and region:
Multi Cancer Early Detection, Type Outlook (Revenue - USD Million, 2019 - 2032)
- Liquid Biopsy
- Gene Panel, LDT & Others
Multi Cancer Early Detection End-use Outlook (Revenue - USD Million, 2019 - 2032)
- Hospitals
- Diagnostic Laboratories
- Other
Multi Cancer Early Detection, Regional Outlook (Revenue - USD Million, 2019 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Latin America
- Argentina
- Brazil
- Mexico
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Multi Cancer Early Detection Market Insights
- 4.1. Multi Cancer Early Detection Market - Industry Snapshot
- 4.2. Multi Cancer Early Detection Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Multi-Cancer Early Detection (MCED) Tests Transforming Cancer Screening with AI Integration
- 4.2.1.2. Enhancing Cancer Detection Rates
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Potential Risks and Uncertainties Surrounding Multi-Cancer Early Detection Tests
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis<
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTLE Analysis
- 4.5. Multi Cancer Early Detection Industry trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Multi Cancer Early Detection Market, by Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Multi Cancer Early Detection, by Type, 2019-2032 (USD Million)
- 5.3. Liquid Biopsy
- 5.3.1. Global Multi Cancer Early Detection Market, by Liquid Biopsy, by Region, 2019-2032 (USD Million)
- 5.4. Gene Panel, LDT
- 5.4.1. Global Multi Cancer Early Detection Market, by Gene Panel, LDT, by Region, 2019-2032 (USD Million)
- 5.5. Others
- 5.5.1. Global Multi Cancer Early Detection Market, by Others, by Region, 2019-2032 (USD Million)
6. Global Multi Cancer Early Detection Market, by End User
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 6.3. Hospitals
- 6.3.1. Global Multi Cancer Early Detection Market, by Hospitals, by Region, 2019-2032 (USD Million)
- 6.4. Diagnostic Laboratories
- 6.4.1. Global Multi Cancer Early Detection Market, by Diagnostic Laboratories, by Region, 2019-2032 (USD Million)
- 6.5. Others
- 6.5.1. Global Multi Cancer Early Detection Market, by Others, by Region, 2019-2032 (USD Million)
7. Global Multi Cancer Early Detection Market, by Geography
- 7.1. Key findings
- 7.2. Introduction
- 7.2.1. Multi Cancer Early Detection Market Assessment, By Geography, 2019-2032 (USD Million)
- 7.3. Multi Cancer Early Detection Market - North America
- 7.3.1. North America: Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 7.3.2. North America: Multi Cancer Early Detection Market, by Type, 2019-2032 (USD Million)
- 7.3.3. Multi Cancer Early Detection Market - U.S.
- 7.3.3.1. U.S.: Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 7.3.3.2. U.S.: Multi Cancer Early Detection Market, by Type, 2019-2032 (USD Million)
- 7.3.4. Multi Cancer Early Detection Market - Canada
- 7.3.4.1. Canada: Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 7.3.4.2. Canada: Multi Cancer Early Detection Market, by Type, 2019-2032 (USD Million)
- 7.4. Multi Cancer Early Detection Market - Europe
- 7.4.1. Europe: Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 7.4.2. Europe: Multi Cancer Early Detection Market, by Type, 2019-2032 (USD Million)
- 7.4.3. Multi Cancer Early Detection Market - UK
- 7.4.3.1. UK: Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 7.4.3.2. UK: Multi Cancer Early Detection Market, by Type, 2019-2032 (USD Million)
- 7.4.4. Multi Cancer Early Detection Market - France
- 7.4.4.1. France: Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 7.4.4.2. France: Multi Cancer Early Detection Market, by Type, 2019-2032 (USD Million)
- 7.4.5. Multi Cancer Early Detection Market - Germany
- 7.4.5.1. Germany: Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 7.4.5.2. Germany: Multi Cancer Early Detection Market, by Type, 2019-2032 (USD Million)
- 7.4.6. Multi Cancer Early Detection Market - Italy
- 7.4.6.1. Italy: Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 7.4.6.2. Italy: Multi Cancer Early Detection Market, by Type, 2019-2032 (USD Million)
- 7.4.7. Multi Cancer Early Detection Market - Spain
- 7.4.7.1. Spain: Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 7.4.7.2. Spain: Multi Cancer Early Detection Market, by Type, 2019-2032 (USD Million)
- 7.4.8. Multi Cancer Early Detection Market - Netherlands
- 7.4.8.1. Netherlands: Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 7.4.8.2. Netherlands: Multi Cancer Early Detection Market, by Type, 2019-2032 (USD Million)
- 7.4.9. Multi Cancer Early Detection Market - Russia
- 7.4.9.1. Russia: Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 7.4.9.2. Russia: Multi Cancer Early Detection Market, by Type, 2019-2032 (USD Million)
- 7.5. Multi Cancer Early Detection Market - Asia Pacific
- 7.5.1. Asia Pacific: Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 7.5.2. Asia Pacific: Multi Cancer Early Detection Market, by Type, 2019-2032 (USD Million)
- 7.5.3. Multi Cancer Early Detection Market - China
- 7.5.3.1. China: Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 7.5.3.2. China: Multi Cancer Early Detection Market, by Type, 2019-2032 (USD Million)
- 7.5.4. Multi Cancer Early Detection Market - India
- 7.5.4.1. India: Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 7.5.4.2. India: Multi Cancer Early Detection Market, by Type, 2019-2032 (USD Million)
- 7.5.5. Multi Cancer Early Detection Market - Malaysia
- 7.5.5.1. Malaysia: Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 7.5.5.2. Malaysia: Multi Cancer Early Detection Market, by Type, 2019-2032 (USD Million)
- 7.5.6. Multi Cancer Early Detection Market - Japan
- 7.5.6.1. Japan: Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 7.5.6.2. Japan: Multi Cancer Early Detection Market, by Type, 2019-2032 (USD Million)
- 7.5.7. Multi Cancer Early Detection Market - Indonesia
- 7.5.7.1. Indonesia: Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 7.5.7.2. Indonesia: Multi Cancer Early Detection Market, by Type, 2019-2032 (USD Million)
- 7.5.8. Multi Cancer Early Detection Market - South Korea
- 7.5.8.1. South Korea: Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 7.5.8.2. South Korea: Multi Cancer Early Detection Market, by Type, 2019-2032 (USD Million)
- 7.6. Multi Cancer Early Detection Market - Middle East & Africa
- 7.6.1. Middle East & Africa: Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 7.6.2. Middle East & Africa: Multi Cancer Early Detection Market, by Type, 2019-2032 (USD Million)
- 7.6.3. Multi Cancer Early Detection Market - Saudi Arabia
- 7.6.3.1. Saudi Arabia: Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 7.6.3.2. Saudi Arabia: Multi Cancer Early Detection Market, by Type, 2019-2032 (USD Million)
- 7.6.4. Multi Cancer Early Detection Market - UAE
- 7.6.4.1. UAE: Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 7.6.4.2. UAE: Multi Cancer Early Detection Market, by Type, 2019-2032 (USD Million)
- 7.6.5. Multi Cancer Early Detection Market - Israel
- 7.6.5.1. Israel: Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 7.6.5.2. Israel: Multi Cancer Early Detection Market, by Type, 2019-2032 (USD Million)
- 7.6.6. Multi Cancer Early Detection Market - South Africa
- 7.6.6.1. South Africa: Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 7.6.6.2. South Africa: Multi Cancer Early Detection Market, by Type, 2019-2032 (USD Million)
- 7.7. Multi Cancer Early Detection Market - Latin America
- 7.7.1. Latin America: Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 7.7.2. Latin America: Multi Cancer Early Detection Market, by Type, 2019-2032 (USD Million)
- 7.7.3. Multi Cancer Early Detection Market - Mexico
- 7.7.3.1. Mexico: Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 7.7.3.2. Mexico: Multi Cancer Early Detection Market, by Type, 2019-2032 (USD Million)
- 7.7.4. Multi Cancer Early Detection Market - Brazil
- 7.7.4.1. Brazil: Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 7.7.4.2. Brazil: Multi Cancer Early Detection Market, by Type, 2019-2032 (USD Million)
- 7.7.5. Multi Cancer Early Detection Market - Argentina
- 7.7.5.1. Argentina: Multi Cancer Early Detection Market, by End User, 2019-2032 (USD Million)
- 7.7.5.2. Argentina: Multi Cancer Early Detection Market, by Type, 2019-2032 (USD Million)
8. Competitive Landscape
- 8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
- 8.2. Partnerships/Collaborations/Agreements/Exhibitions
9. Company Profiles
- 9.1. Illumina, Inc. (GRAIL, LLC)
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
- 9.2. Exact Sciences Corp.
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
- 9.3. Foundation Medicine, Inc
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
- 9.4. AnchorDx
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
- 9.5. Guardant Health
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
- 9.6. Burning Rock Biotech Ltd
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
- 9.7. GENECAST
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
- 9.8. Beijing Lyman Juntai International Medical Technology Development Co
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
- 9.9. Freenome Holdings, Inc.
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
- 9.10. Elypta AB
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development
